Clinical Outcome with Intravitreal Brolucizumab for Retinal Vein Occlusion

Authors

  • Dilara Khatun Consultant Ophthalmologist, Bangladesh Eye Hospital & Institute, Dhaka, Bangladesh
  • Md Ziaul Ahsan Consultant Ophthalmologist, Bangladesh Eye Hospital & Institute, Dhaka, Bangladesh
  • Syeed Mehbub Ul Kadir Consultant Ophthalmologist, Bangladesh Eye Hospital & Institute, Dhaka, Bangladesh
  • Razia Shultana Associate Researcher, Bangladesh Eye Hospital & Institute, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/cbmj.v14i2.83323

Keywords:

Brolucizumab, retinal vein occlusion, macular oedema, anti-VEGF agent, intravitreal injection

Abstract

This case study tends to report that to what extent a patient with retinal vein occlusion positively responding to intravitreal injection of Brolucizumab. In this case, Brolucizumab was recommended for a 60-year-old female who primarily presented with signs of visual loss. The best corrected visual acuity recorded as CF at 3 ft (ability to count fingers at 3 feet) in her right eye and 6/12 of the left eye. The Intraocular pressure (IOP) was 18 mmHg (right) and 24 mmHg (left). The Central corneal thickness (CCT) was 530 μm (both eyes). Lental opacity was observed in both eyes. The patient achieved significant visual improvement after a one-year follow-up with brolucizumab. There were no serious adverse effects. With appropriate monitoring, brolucizumab appears to be safe and beneficial for patients with retinal vein occlusion.  

CBMJ 2025 July: vol. 14 no. 02 P:198-200

Downloads

Download data is not yet available.
Abstract
96
PDF
36

Downloads

Published

2025-07-28

How to Cite

Khatun, D., Ahsan, M. Z., Kadir, S. M. U., & Shultana, R. (2025). Clinical Outcome with Intravitreal Brolucizumab for Retinal Vein Occlusion. Community Based Medical Journal, 14(2), 198–200. https://doi.org/10.3329/cbmj.v14i2.83323

Issue

Vol. 14 No. 2 (2025)

Section

Case Reports

License

Copyright (c) 2025 Dilara Khatun, Md Ziaul Ahsan, Syeed Mehbub Ul Kadir, Razia Shultana

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

No part of the materials published in this journal may be reproduced, stored or transmitted without prior written permission of the editorial board.